A Nature Biotechnology paper described delivery of antimicrobial peptides encoded as mRNA 'peptibodies' formulated in anti‑inflammatory lipid carriers to the mouse lung; investigators reported eradication of multidrug‑resistant bacterial pneumonia and reduced markers of pulmonary inflammation. The approach couples rapid mRNA production with engineered peptide scaffolds to improve stability and potency in situ. Authors emphasized the platform’s ability to bypass traditional antibiotic resistance mechanisms and its modularity for targeting diverse pathogens. The work demonstrates a translational path for nucleic‑acid‑encoded biologics as a complementary strategy to small‑molecule antibiotics in difficult pulmonary infections. Clarification: 'Peptibody mRNA' encodes short antimicrobial peptide sequences fused to stabilizing scaffolds so the host translates and displays an active antimicrobial agent at the site of infection.